article · South African Journal of Oncology
Background: Hepatoblastoma (HB) is the most common solid liver cancer in childhood. Globally, survival has significantly improved with advanced treatment modalities. However, survival is poor in low-middle-income countries (LMICs) due to advanced-stage presentation. Aim: The aim was to evaluate the incidence and outcomes of children diagnosed with HB in relation to prognostic indicators which included age, sex, PRE-Treatment EXTent (PRETEXT) staging, metastasis and surgical intervention. Outcomes included survival and mortality. Setting: The research was conducted at the Pediatric Oncology Unit in Universitas Academic Hospital in Bloemfontein, South Africa, which serves as a tertiary referal centre for patients from the Northern Cape, Free State and Lesotho. Methods: We retrospectively analysed medical records of the children with HB diagnosed and treated from 2000 till 2022 at Universitas Academic Hospital Paediatric Oncology Unit. Results: Twenty patients were included with an incidence of 1.2% and a 95% confidence interval (CI) of 0.8%–1.8%. Median age was 2 years old with interquartile range (IQR) of 1 year – 2.97 years. There was a male: female ratio of 1.9:1. All children presented with abdominal distension and elevated alpha fetoprotein (AFP) levels. More than half (55%; n = 11) had PRETEXT IV and 45% (n = 9) had lung metastasis at presentation. Surgical resection was done in 50% (n = 10) and none had liver transplant. The 1 year overall survival (OS) was 55% (n = 11), 2-year OS was 20% (n = 4), and 5 year OS was 10% (n = 2). Higher mortality was noted in children above 3 years old (p = 0.5304), male patients (p = 0.1011), distant metastasis (p = 0.5913), PRETEXT stage IV (p = 0.2621), high risk HB (p = 0.117) and children who did not get surgical resection (p = 0.0867). Conclusion: Survival was negatively impacted by older age, male gender, advanced stage of disease and paucity of surgical intervention. Contribution: This study highlights the factors affecting the survival of children with this rare disease and highlights measures to improve same.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.4102/sajo.v10i0.369
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.